Stroke concern with atrial fibrillation rather than SVT
PITFALLS
Regular tachycardia at 150
Atrial flutter with 2 to 1 conduction masquerading as SVT
Wide complex tachycardia
Ventricular tachycardia until proven otherwise
Differential Diagnosis
Narrow complex tachycardia differentials
SVT mechanisms
AV nodal reentrant tachycardia
ICD-10 I47.1
SNOMED CT supraventricular tachycardia
AV reentrant tachycardia via accessory pathway
Wolff Parkinson White pattern association
Atrial tachycardia
Focal or multifocal atrial tachycardia
Atrial fibrillation or flutter
Atrial flutter
Sawtooth flutter waves with variable recognition
ICD-10 I48.3
Atrial fibrillation
Irregularly irregular rhythm
ICD-10 I48.91
Sinus tachycardia causes
Sepsis
Fever, hypotension, infection source
Hypovolemia
Bleeding, dehydration
Pain or anxiety
Context dependent
Pulmonary embolism
Pleuritic pain, hypoxemia, risk factors
Thyrotoxicosis
Tremor, weight loss
Wide complex mimics
Ventricular tachycardia
ICD-10 I47.2
SVT with aberrancy
Bundle branch block pattern
Preexcited tachycardias
Antidromic AVRT
Preexcited atrial fibrillation
Laboratory Tests
Core labs and indications
Metabolic and endocrine assessment
Electrolytes
Potassium for hypokalemia trigger
Magnesium for hypomagnesemia trigger
Calcium for hypocalcemia trigger
Renal function
Medication selection and dosing safety
Thyroid function tests
Persistent unexplained tachyarrhythmia
Hematology and perfusion
Complete blood count
Anemia trigger for tachycardia
Infection signal if febrile
Lactate
Shock or hypoperfusion concern
Cardiac injury evaluation
Troponin
Ischemic symptoms or high risk features
Demand ischemia interpretation caution
Pregnancy testing
Beta hCG
Reproductive age with unclear status
Toxicology considerations
Targeted tox screen
Suspected stimulant use
Suspected overdose
PITFALLS
Troponin elevation
Tachycardia related demand ischemia without acute coronary occlusion
Electrolytes reported normal
Rapid shifts possible after fluids or vomiting
Diagnostic Tests
Scoring Systems
Tachycardia algorithm framework
ACLS stable tachycardia approach
Narrow regular tachycardia pathway
Vagal maneuvers first line in stable regular SVT
Unstable tachycardia definition
Hypotension attributable to rhythm
Ischemic chest discomfort
Acute heart failure
Altered mental status
Wide complex differentiation aids
Clinical safety principle
Treat unknown wide complex as ventricular tachycardia
Avoid AV nodal blockers in irregular wide complex tachycardia
ECG algorithm use
Brugada criteria concept for VT likelihood
Vereckei aVR approach concept for VT likelihood
MRI
Cardiac MRI indications
Structural heart disease evaluation
Suspected cardiomyopathy with recurrent SVT
Congenital heart disease anatomy clarification
Myocarditis evaluation
Chest pain with troponin elevation not explained by demand alone
Cardiac MRI limitations
Not an acute SVT diagnostic test
Timing after stabilization preferred
Implantable device compatibility constraints
MRI conditional status confirmation
CT
CT use cases in SVT presentations
Pulmonary embolism evaluation
CT pulmonary angiography for PE suspicion
Coronary CT angiography
Selected low to intermediate risk chest pain after rhythm control
CT limitations
Not required for typical uncomplicated SVT
Avoid radiation and contrast when low yield
Ultrasound
Point of care echocardiography
Global systolic function
Tachycardia induced cardiomyopathy suspicion
Volume status markers
IVC size and collapsibility as supportive data
Pericardial effusion
Tamponade physiology if hypotensive
Lung ultrasound
B lines pattern
Pulmonary edema assessment in dyspnea
Pleural effusion
Alternative dyspnea contributors
Disposition
Level of care and follow up
Discharge eligibility
Hemodynamic stability after conversion
Normal mentation
No ongoing chest discomfort
No acute heart failure
No pulmonary edema findings
Reversible trigger addressed
Electrolyte repletion completed if needed
Reliable follow up
Primary care or cardiology arranged
Observation or admission
High risk features
Syncope
Suspected ventricular tachycardia
Persistent or recurrent SVT in ED
Multiple pharmacologic attempts required
Cardiac ischemia concern
Dynamic ECG changes
Rising troponin pattern with symptoms
Significant comorbidity
Heart failure
Significant structural disease
Transfer criteria
Need for electrophysiology intervention unavailable locally
Refractory arrhythmia
Suspected high risk accessory pathway complications
Treatment
Stable regular narrow complex SVT
Nonpharmacologic conversion
Vagal maneuvers
Modified Valsalva technique
Strain 15 seconds in semi recumbent position
Immediate supine reposition with leg elevation
Carotid sinus massage contraindications
Carotid bruit or known carotid stenosis
Recent stroke or TIA
Pharmacologic conversion and diagnosis
Adenosine
Contraindications and cautions
Severe asthma with active bronchospasm
Irregular wide complex tachycardia
Dosing and administration
IV 6 mg rapid push followed by saline flush
If no conversion within 1 to 2 minutes, IV 12 mg rapid push followed by saline flush
IV 12 mg repeat dose if no conversion
Maximum total 30 mg typical practice
Administration optimization
Proximal IV site
Large bore IV in antecubital or central access preferred
Two syringe technique
Immediate flush to deliver bolus
Expected ECG effects
Transient AV block
Diagnostic unmasking of flutter waves or atrial tachycardia
Calcium channel blockers for stable SVT
Diltiazem IV
IV 0.25 mg per kg over 2 minutes
Maximum initial dose 20 mg
If inadequate response after 15 minutes, IV 0.35 mg per kg over 2 minutes
Maximum second dose 25 mg
Continuous infusion
IV 5 mg per hour start
Titration 2.5 mg per hour increments
Maximum 15 mg per hour
Verapamil IV
IV 2.5 to 5 mg slow over 2 minutes
If inadequate response, repeat 5 to 10 mg after 15 to 30 minutes
Maximum total 20 mg
Avoid in hypotension
Beta blockers for stable SVT
Metoprolol IV
IV 2.5 to 5 mg slow push
Repeat every 5 minutes as needed
Maximum total 15 mg
Avoid in acute decompensated heart failure
Esmolol IV
IV 500 microgram per kg bolus over 1 minute
Continuous infusion 50 microgram per kg per minute
Titration
Increase by 50 microgram per kg per minute every 5 to 10 minutes
Maximum 200 microgram per kg per minute common practice
Electrical therapy in stable patient
Synchronized cardioversion
Narrow regular SVT energy selection
50 to 100 J biphasic initial
Escalation if unsuccessful
Unstable SVT
Immediate synchronized cardioversion
Sedation if time and stability allow
Etomidate IV 0.15 mg per kg single dose
Ketamine IV 1 mg per kg single dose
Energy selection
Narrow regular SVT 50 to 100 J biphasic
Escalation to higher energies if needed
Post conversion management
Trigger treatment
Electrolyte repletion
Sepsis treatment if indicated
Recurrence prevention
Cardiology input for maintenance strategy
Wide complex tachycardia considerations
Regular monomorphic wide complex tachycardia
Adenosine diagnostic trial conditions
Regular rhythm
No preexcited atrial fibrillation features
If no response or instability, ventricular tachycardia pathway
Synchronized cardioversion if unstable
Irregular wide complex tachycardia
Preexcited atrial fibrillation concern
Avoid AV nodal blockers
Cardiology consultation
Refractory or recurrent SVT
Antiarrhythmic strategies
Procainamide IV for selected pathways
IV 20 to 50 mg per minute until arrhythmia suppression
Maximum 17 mg per kg total dose
Stop criteria
Hypotension
QRS widening over 50 percent
Maximum dose reached
Maintenance infusion
IV 1 to 4 mg per minute
Amiodarone role
Less preferred for typical AVNRT AVRT conversion
Use per ventricular tachycardia protocol when appropriate
Definitive therapy referral
Catheter ablation
Symptomatic recurrent SVT
Patient preference to avoid long term medications
Special Populations
Pregnancy
Physiologic considerations
Increased resting heart rate
Higher baseline rates complicate thresholds
Aortocaval compression
Left uterine displacement in late pregnancy during resuscitation
Acute management preferences
Vagal maneuvers first line
Modified Valsalva suitable
Adenosine safety
Very short half life and minimal fetal exposure expectation
Synchronized cardioversion safety
Acceptable in all trimesters for maternal instability
Medication cautions
Calcium channel blockers
Maternal hypotension risk
Beta blockers
Fetal growth effects with long term therapy consideration
Geriatric
Presentation and risk
Higher likelihood structural heart disease
Lower tolerance of tachycardia
Atypical symptoms
Weakness or confusion rather than palpitations
Treatment cautions
Adenosine sensitivity
Start standard dosing with readiness for bradycardia management
Diltiazem and verapamil
Hypotension and heart failure precipitation risk
Beta blockers
Conduction disease risk
Pediatrics
Presentation differences
Infants
Poor feeding
Irritability
Pallor
Older children
Palpitations
Dizziness
Vagal maneuvers
Ice to face technique
10 to 20 seconds with airway monitoring
Valsalva coaching
Age appropriate instructions
Medications and energy dosing
Adenosine weight based dosing
IV 0.1 mg per kg rapid push
Maximum single dose 6 mg
If no conversion, IV 0.2 mg per kg rapid push
Maximum single dose 12 mg
Synchronized cardioversion weight based energy
0.5 to 1 J per kg initial
Escalation to 2 J per kg
Background
Epidemiology
Frequency and demographics
Common ED tachyarrhythmia category
AVNRT common in adults
AVRT more common in younger patients with accessory pathways
Female predominance for AVNRT
Observational registry trend
Natural history
Recurrent episodic pattern
Variable frequency
Rare progression to hemodynamic collapse without comorbidity
Pathophysiology
Reentry mechanisms
AV nodal reentry
Dual AV nodal pathways
Slow pathway antegrade with fast pathway retrograde typical
Accessory pathway mediated reentry
AVRT circuit using atrium AV node ventricle accessory pathway
Orthodromic AVRT narrow complex typical
Trigger physiology
Premature atrial beats
Initiation of reentry circuit
Autonomic tone influence
Vagal maneuvers increase AV nodal refractoriness
Therapeutic Considerations
AV nodal dependence
AVNRT and orthodromic AVRT
Sensitive to AV nodal blockade
Vagal maneuvers and adenosine high effectiveness
Adenosine pharmacology
Very short half life
Rapid bolus and flush required
Transient AV block
Diagnostic utility for atrial flutter and atrial tachycardia
Calcium channel blocker considerations
Negative inotropy
Avoid in severe LV dysfunction or decompensated heart failure
Definitive cure option
Catheter ablation success
High long term success rates in experienced centers
Complication risk discussion required
Patient Discharge Instructions
copy discharge instructions
Home care and prevention
Trigger reduction
Limit caffeine and energy drinks
Avoid stimulant decongestants
Hydration and sleep optimization
Vagal maneuver practice
Modified Valsalva steps reviewed for recurrence
Stop if chest pain, severe dizziness, or near fainting
Medications and safety
Take prescribed rate control medication as directed
Do not double doses for missed doses
Avoid new over the counter stimulants
Ask pharmacist or clinician before use
Return to ED immediately for
Fainting or near fainting
Chest pain or pressure
Shortness of breath at rest
New weakness on one side, trouble speaking, or severe confusion
Palpitations lasting over 20 to 30 minutes despite vagal maneuvers
Heart rate very fast with dizziness or low blood pressure symptoms
Follow up plan
Primary care or cardiology within 1 to 2 weeks
Earlier follow up if recurrent episodes
Ambulatory monitoring discussion
Holter or event monitor if diagnosis uncertain
Electrophysiology referral discussion
Recurrent symptomatic SVT or patient preference for ablation
References
Clinical guidelines and key sources
Guideline and consensus sources
ACC AHA HRS guideline for management of adult SVT including AVNRT AVRT and atrial tachycardia
Evidence classes commonly reported as Class I IIa IIb
Catheter ablation as definitive therapy for recurrent symptomatic SVT
AHA ACLS tachycardia algorithm for stable versus unstable tachycardia
Synchronized cardioversion for unstable tachycardia
Adenosine for regular narrow complex tachycardia
Evidence summaries and reviews
Modified Valsalva technique trials in ED SVT conversion
Higher conversion rates than standard Valsalva in adult ED cohorts
Low adverse event rates with appropriate patient selection
Adenosine safety and effectiveness literature
High acute conversion rates in AV node dependent SVT
Transient adverse effects common and self limited
Calcium channel blocker and beta blocker comparative data
Similar conversion or rate control effectiveness in selected stable patients
Hypotension risk emphasized in older and heart failure populations
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.